• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突尼斯苏塞一家教学医院中产生新德里金属β-内酰胺酶(NDM)的菌株的克隆传播

Clonal Dissemination of NDM-Producing in a Teaching Hospital in Sousse, Tunisia.

作者信息

Jaidane Nadia, Tilouche Lamia, Oueslati Saoussen, Girlich Delphine, Azaiez Sana, Jacquemin Aymeric, Dortet Laurent, Naija Walid, Trabelsi Abdelhalim, Naas Thierry, Mansour Wejdene, Bonnin Rémy A

机构信息

Laboratory of Metabolic Biophysics and Applied Pharmacology (LR12ES02), Department of Biophysics, Faculty of Medicine Ibn El Jazzar of Sousse, University of Sousse, Sousse 4000, Tunisia.

Clinical Microbiology Laboratory, University Hospital of Sahloul, Sousse 4002, Tunisia.

出版信息

Pathogens. 2025 Mar 20;14(3):298. doi: 10.3390/pathogens14030298.

DOI:10.3390/pathogens14030298
PMID:40137783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11946351/
Abstract

() is an opportunistic pathogen involved in urinary tract infections as well as various nosocomial infections. Emerging resistances to beta-lactams in this species complicates potential treatment since it is intrinsically resistant to colistin. Eleven isolates of carbapenem-non-susceptible were identified in Sousse Hospital, Tunisia, from January 2018 to December 2022. MICs were determined and isolates were sequenced to determine their resistomes, sequence types, virulence factors, and their clonal relationships. Susceptibility testing showed that all isolates were resistant to carbapenems, aminoglycosides, fluoroquinolones, chloramphenicol, and the trimethoprim/sulfamethoxazole combination. They remained susceptible to the aztreonam/avibactam combination. All isolates produced NDM-1 carbapenemase and ArmA 16S rRNA methylase. In addition, one isolate co-produced the gene. All isolates belonged to ST135, and phylogenetic analysis revealed that they were closely related. This study described the first outbreak of NDM-1-producing in Tunisia.

摘要

(某菌)是一种机会致病菌,可引发尿路感染及多种医院感染。该菌种对β-内酰胺类药物出现的新耐药性使潜在治疗变得复杂,因为它对黏菌素具有固有耐药性。2018年1月至2022年12月期间,在突尼斯苏塞医院鉴定出11株对碳青霉烯类不敏感的(某菌)分离株。测定了最低抑菌浓度(MIC),并对分离株进行测序以确定其耐药组、序列类型、毒力因子及其克隆关系。药敏试验表明,所有分离株均对碳青霉烯类、氨基糖苷类、氟喹诺酮类、氯霉素以及甲氧苄啶/磺胺甲恶唑合剂耐药。它们对氨曲南/阿维巴坦合剂仍敏感。所有分离株均产生NDM-1碳青霉烯酶和ArmA 16S rRNA甲基化酶。此外,一株分离株还共同产生了(另一)基因。所有分离株均属于ST135,系统发育分析表明它们密切相关。本研究描述了突尼斯首次出现的产NDM-1(某菌)疫情。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa01/11946351/de2bc76c711d/pathogens-14-00298-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa01/11946351/de2bc76c711d/pathogens-14-00298-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa01/11946351/de2bc76c711d/pathogens-14-00298-g001.jpg

相似文献

1
Clonal Dissemination of NDM-Producing in a Teaching Hospital in Sousse, Tunisia.突尼斯苏塞一家教学医院中产生新德里金属β-内酰胺酶(NDM)的菌株的克隆传播
Pathogens. 2025 Mar 20;14(3):298. doi: 10.3390/pathogens14030298.
2
Clonal outbreak caused by VIM-4-producing Proteus mirabilis in a Greek tertiary-care hospital.产 VIM-4 奇异变形杆菌引起的克隆爆发在一家希腊三级保健医院。
Int J Antimicrob Agents. 2020 Aug;56(2):106060. doi: 10.1016/j.ijantimicag.2020.106060. Epub 2020 Jun 20.
3
Characterization of the Genetic Environment of the bla Gene, Associated with a Transposable Region in a Proteus mirabilis Clinical Isolate.与奇异变形杆菌临床分离株中一个可转座区域相关的bla基因的遗传环境特征分析
Microb Drug Resist. 2017 Oct;23(7):833-837. doi: 10.1089/mdr.2016.0262. Epub 2017 Mar 17.
4
Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.韩国一家大学医院中奇异变形杆菌产生超广谱β-内酰胺酶VEB-1导致的医院感染暴发。
J Antimicrob Chemother. 2004 Dec;54(6):1144-7. doi: 10.1093/jac/dkh486. Epub 2004 Nov 16.
5
First report of extensively-drug-resistant Proteus mirabilis isolate carrying plasmid-mediated bla in a Tunisian intensive care unit.首报来自于突尼斯重症监护病房携带可移动 bla 基因的广泛耐药奇异变形杆菌。
Int J Antimicrob Agents. 2018 Dec;52(6):906-909. doi: 10.1016/j.ijantimicag.2018.06.009. Epub 2018 Jun 26.
6
Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.日本产奇异变形杆菌中产 CTX-M-2 型β-内酰胺酶的区域性爆发。
J Med Microbiol. 2012 Dec;61(Pt 12):1727-1735. doi: 10.1099/jmm.0.049726-0. Epub 2012 Aug 30.
7
First report of bla carbapenemase gene, armA methyltransferase and aac(6')-Ib-cr among multidrug-resistant clinical isolates of Proteus mirabilis in Algeria.首次在阿尔及利亚多重耐药性奇异变形杆菌临床分离株中发现 bla 碳青霉烯酶基因、armA 甲基转移酶和 aac(6')-Ib-cr。
J Glob Antimicrob Resist. 2019 Mar;16:125-129. doi: 10.1016/j.jgar.2018.08.019. Epub 2018 Sep 11.
8
Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.阿尔及利亚奇异变形杆菌临床分离株中新出现的多药耐药性的分子驱动因素。
J Glob Antimicrob Resist. 2019 Sep;18:249-256. doi: 10.1016/j.jgar.2019.01.030. Epub 2019 Feb 21.
9
Carbapenem-Susceptible OXA-23-Producing Proteus mirabilis in the French Community.产 OXA-23 碳青霉烯类药物敏感奇异变形杆菌在法国社区。
Antimicrob Agents Chemother. 2019 May 24;63(6). doi: 10.1128/AAC.00191-19. Print 2019 Jun.
10
Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.奇异变形杆菌的抗菌药敏性:来自台湾抗菌药物耐药性监测计划(TSAR)的全国性纵向研究。
BMC Infect Dis. 2014 Sep 5;14:486. doi: 10.1186/1471-2334-14-486.

引用本文的文献

1
Genomic Insights of Emerging Multidrug-Resistant OXA-48-Producing ST135 .产OXA-48的ST135型新兴多重耐药菌的基因组学见解
Antibiotics (Basel). 2025 Jul 25;14(8):750. doi: 10.3390/antibiotics14080750.

本文引用的文献

1
The burden of hospital acquired infections and antimicrobial resistance.医院获得性感染和抗菌药物耐药性的负担。
Heliyon. 2023 Oct 2;9(10):e20561. doi: 10.1016/j.heliyon.2023.e20561. eCollection 2023 Oct.
2
Proteus mirabilis: A rare cause of pneumonia, radiologically mimicking malignancy of the lung.奇异变形杆菌:一种罕见的肺炎病因,在放射学上酷似肺癌。
Clin Case Rep. 2023 Sep 19;11(9):e7937. doi: 10.1002/ccr3.7937. eCollection 2023 Sep.
3
Genetic analysis of resistance and virulence characteristics of clinical multidrug-resistant isolates.
临床多重耐药分离株的耐药性和毒力特征的遗传分析。
Front Cell Infect Microbiol. 2023 Aug 11;13:1229194. doi: 10.3389/fcimb.2023.1229194. eCollection 2023.
4
Proteus mirabilis - analysis of a concealed source of carbapenemases and development of a diagnostic algorithm for detection.奇异变形杆菌——碳青霉烯酶隐匿来源分析与检测诊断算法的建立
Clin Microbiol Infect. 2023 Sep;29(9):1198.e1-1198.e6. doi: 10.1016/j.cmi.2023.05.032. Epub 2023 Jun 2.
5
Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates.奇异变形杆菌临床分离株中广泛β-内酰胺酶、AmpC 和碳青霉烯酶的流行率。
BMC Microbiol. 2022 Oct 11;22(1):247. doi: 10.1186/s12866-022-02662-3.
6
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担:系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
7
Intracellular Transposition and Capture of Mobile Genetic Elements following Intercellular Conjugation of Multidrug Resistance Conjugative Plasmids from Clinical Isolates.临床分离株多重耐药接合型质粒通过细胞间接合实现的细胞内转座和移动遗传元件捕获。
Microbiol Spectr. 2022 Feb 23;10(1):e0214021. doi: 10.1128/spectrum.02140-21. Epub 2022 Jan 19.
8
Virulence factors of Proteus mirabilis clinical isolates carrying bla and bla and first report bla in Brazil.巴西产携带 bla 和 bla 以及首个 bla 的奇异变形杆菌临床分离株的毒力因子。
J Infect Chemother. 2022 Mar;28(3):363-372. doi: 10.1016/j.jiac.2021.11.001. Epub 2021 Nov 21.
9
Towards the sustainable discovery and development of new antibiotics.迈向新型抗生素的可持续发现与开发。
Nat Rev Chem. 2021;5(10):726-749. doi: 10.1038/s41570-021-00313-1. Epub 2021 Aug 19.
10
New Perspectives on Antimicrobial Agents: Cefiderocol.抗菌药物新视角:头孢地尔。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0217120. doi: 10.1128/AAC.02171-20.